JP2001507342A5 - - Google Patents

Download PDF

Info

Publication number
JP2001507342A5
JP2001507342A5 JP1998527715A JP52771598A JP2001507342A5 JP 2001507342 A5 JP2001507342 A5 JP 2001507342A5 JP 1998527715 A JP1998527715 A JP 1998527715A JP 52771598 A JP52771598 A JP 52771598A JP 2001507342 A5 JP2001507342 A5 JP 2001507342A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1998527715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001507342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/021532 external-priority patent/WO1998026773A1/en
Publication of JP2001507342A publication Critical patent/JP2001507342A/ja
Publication of JP2001507342A5 publication Critical patent/JP2001507342A5/ja
Abandoned legal-status Critical Current

Links

JP52771598A 1996-12-17 1997-11-21 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用 Abandoned JP2001507342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3275396P 1996-12-17 1996-12-17
US60/032,753 1996-12-17
PCT/US1997/021532 WO1998026773A1 (en) 1996-12-17 1997-11-21 Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing

Publications (2)

Publication Number Publication Date
JP2001507342A JP2001507342A (ja) 2001-06-05
JP2001507342A5 true JP2001507342A5 (enExample) 2005-07-14

Family

ID=21866631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52771598A Abandoned JP2001507342A (ja) 1996-12-17 1997-11-21 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用

Country Status (14)

Country Link
US (1) US6340709B1 (enExample)
EP (1) EP0946166B1 (enExample)
JP (1) JP2001507342A (enExample)
AT (1) ATE259640T1 (enExample)
AU (1) AU737117B2 (enExample)
BR (1) BR9714142A (enExample)
CA (1) CA2264692A1 (enExample)
DE (1) DE69727695T2 (enExample)
DK (1) DK0946166T3 (enExample)
ES (1) ES2212142T3 (enExample)
NZ (1) NZ334925A (enExample)
PT (1) PT946166E (enExample)
WO (1) WO1998026773A1 (enExample)
ZA (1) ZA9711279B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225779T1 (de) * 1995-11-17 2002-10-15 Warner Lambert Co Sulfonamidinhibitoren von matrix metalloproteinasen
CZ287868B6 (en) * 1995-12-22 2001-02-14 Warner Lambert Co Aromatic keto-acids and their derivatives functioning as inhibitors of matrix metalloproteinases
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
EP1053226A1 (en) 1998-02-04 2000-11-22 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
AU6229699A (en) * 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
JP4074043B2 (ja) 2000-03-27 2008-04-09 株式会社資生堂 皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
WO2002006227A1 (en) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
WO2002026696A1 (en) 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
ATE298565T1 (de) * 2000-11-23 2005-07-15 Vernalis Oxford Ltd N-formyl hydroxylamine derivate als inhibitoren der bakteriellen polypeptid deformylase zur behandlung von mikrobiellen infektionen
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
GB0204159D0 (en) * 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
MX2007001337A (es) * 2004-08-02 2008-03-13 Genmedica Therapeutics Sl Compuestos para inhibir amina-oxidasas que contienen cobre y usos de los mismos.
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
US20090136718A1 (en) * 2007-11-28 2009-05-28 Paul Dacey Reinforced Bonded Constructs
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
CN111249281B (zh) * 2020-03-26 2020-11-24 徐州医科大学 Trpml1特异性小分子抑制剂ml-si3的新用途
CN116209439A (zh) 2020-09-23 2023-06-02 圣裘德儿童研究医院有限公司 作为cereblon蛋白调节剂的取代的N-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)芳基磺酰胺类似物
KR102612229B1 (ko) * 2021-05-21 2023-12-08 가천대학교 산학협력단 N-[(4'-브로모[1,1'-바이페닐]-4-일)설포닐]-l-발린 또는 이의 약제학적으로 허용 가능한 염을 포함하는 아밀로이드 베타의 올리고머화 및 피브릴화 억제용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
ES2133807T3 (es) * 1994-10-05 1999-09-16 Darwin Discovery Ltd Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
ATE206416T1 (de) * 1995-06-02 2001-10-15 Warner Lambert Co Trizyklische verbindungen als matrix- metalloproteinase inhibitoren
ATE225779T1 (de) 1995-11-17 2002-10-15 Warner Lambert Co Sulfonamidinhibitoren von matrix metalloproteinasen
CZ287868B6 (en) 1995-12-22 2001-02-14 Warner Lambert Co Aromatic keto-acids and their derivatives functioning as inhibitors of matrix metalloproteinases
ATE207891T1 (de) * 1996-05-17 2001-11-15 Warner Lambert Co Biphenylsulfonamid matrix metalloproteinase inhibitoren

Similar Documents

Publication Publication Date Title
JP2001505052A5 (enExample)
JP2001506895A5 (enExample)
JP2000507471A5 (enExample)
JP2000513333A5 (enExample)
JP2001500912A5 (enExample)
JP2001506904A5 (enExample)
JP2001506455A5 (enExample)
JP2000504524A5 (enExample)
JP2001501350A5 (enExample)
JP2000514456A5 (enExample)
JP2001507350A5 (enExample)
JP2000503433A5 (enExample)
JP2001502439A5 (enExample)
JP2000507439A5 (enExample)
JP2000503304A5 (enExample)
JP2000507722A5 (enExample)
JP2000510692A5 (enExample)
JP2001500769A5 (enExample)
JP2001507180A5 (enExample)
JP2000506084A5 (enExample)
JP2000511955A5 (enExample)
JP2000516155A5 (enExample)
JP2001501342A5 (enExample)
JP2001501883A5 (enExample)
JP2000506890A5 (enExample)